Keywords
Anti-cancer agent
Adverse reaction
Cancer
Treatment
Submitted : 2023-12-27
Accepted : 2024-01-11
Published : 2024-01-26
Abstract
Cancer stands as one of the major threats to human life. Ensuring the safety of drugs is paramount, and the impact of adverse reactions on patients’ quality of life and prognosis should not be underestimated. Diarrhea is a common clinical adverse event, and despite the absence of specific anti-diarrhea drugs, there is a pressing need for improvement. This article aims to provide a valuable reference for researchers in clinical drug use and scientific tumor treatment. It summarizes recent advancements in drug mechanisms and adverse reactions, whether in preclinical research or clinical diagnosis and therapy.
References
Chen Y, Xu B, 2021, Progress of Tyrosine Kinase Inhibitors in HER-2 Positive Breast Cancer. Chinese Clinical Oncology, 26(3): 265–271.
Wang Y, Qu X, 2021, Progress in Targeted Therapy of HER-2 Positive Breast Cancer. Chinese Journal of Practical Surgery, 41(11): 1304–1308. https://doi.org/10.19538/j.cjps.issn1005-2208.2021.11.22
Ge R, Wang B, Jiang Z, et al., 2022, Expert Consensus on the Management of Adverse Events of CDK4/6 Inhibitors in Breast Cancer. Chinese Journal of Oncology, 44(12): 1296–1304. https://doi.org/10.3760/cma.j.cn112152-20220825-00578
Xie Y-H, Zhou J-Y, Wang J-J, 2022, Research Progress of EGFR Inhibitors. Fine Chemical Intermediates, 2022, 52(4): 6–13. https://doi.org/10.19342/j.cnki.issn.1009-9212.2022.04.002
Zeng Q, Zhang X, He S, et al., 2021, Crizotinib versus Alectinib for the Treatment of ALK-Positive NonSmall Cell Lung Cancer: A Systematic Review and Meta-Analysis. Chemotherapy, 67(2): 67–80. https://doi.org/10.1159/000521452
Kaneda H, Kizaki M, Ochi M, et al., 2020, Ceritinib in Japanese Patients with Anaplastic Lymphoma Kinase (ALK)+ Non-Small Cell Lung Cancer: Interim Analysis Results of a Post-Marketing Surveillance Study. Scientific Reports, 10: 16773. https://doi.org/10.1038/s41598-020-72863-1
Xing P, Hao X, Zhang X, et al., 2022, Efficacy and Safety of Brigatinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Systematic Review and Meta-Analysis. Front Oncol, 12: 920709. https://doi.org/10.3389/fonc.2022.920709
Kassem L, Shohdy KS, Lasheen S, et al., 2019, Safety Issues with the ALK Inhibitors in the Treatment of NSCLC: A Systematic Review. Critical Reviews in Oncology/Hematology, 134: 56–64. https://doi.org/10.1016/j.critrevonc.2018.11.004
Horn L, Infante JR, Reckamp KL, et al., 2018, Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. Clin Cancer Res, 24(12): 2771–2779. https://doi.org/10.1158/1078-0432.CCR-17-2398
Solomon BJ, Besse B, Bauer TM, et al., 2018, Lorlatinib in Patients with ALK-Positive Non-Small-Cell Lung Cancer: Results from a Global Phase 2 Study. The Lancet Oncology, 19(12): 1654–1667. https://doi.org/10.1016/S1470-2045(18)30649-1
Remon J, Pignataro D, Novello S, et al., 2021, Current Treatment and Future Challenges in ROS1- and ALK-Rearranged Advanced Non-Small Cell Lung Cancer. Cancer Treatment Reviews, 95: 102178. https://doi.org/10.1016/j.ctrv.2021.102178
Hellerstedt BA, Vogelzang NJ, Kluger HM, et al., 2019, Results of a Phase II Placebo-Controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-Small-Cell Lung Carcinoma. Clinical Lung Cancer, 20(2): 74–81. https://doi.org/10.1016/j.cllc.2018.10.006
Drilon A, Siena S, Dziadziuszko R, et al., 2020, Entrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer: Integrated Analysis of Three Phase 1–2 Trials. Lancet Oncol, 21(2): 261–270. https://doi.org/10.1016/S1470-2045(19)30690-4
Cho BC, Drilon AE, Doebele RC, et al., 2019, Safety and Preliminary Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive Non-Small Cell Lung Cancer (TRIDENT-1 Study). Journal of Clinical Oncology, 37(15_suppl). https://doi.org/10.1200/JCO.2019.37.15_suppl.9011
Papadopoulos KP, Borazanci E, Shaw AT, et al., 2020, U.S. Phase I First-in-Human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res, 26(18): 4785–4794. https://doi.org/10.1158/1078-0432.CCR-20-1630
Wolf J, Seto T, Han J-Y, et al., 2020, Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med, 383: 944–957. https://doi.org/10.1056/NEJMoa2002787
Mazieres J, Paik PK, Garassino MC, et al., 2023, Tepotinib Treatment in Patients with MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-Term Follow-Up of the VISION Phase 2 Nonrandomized Clinical Trial. JAMA Oncol, 9(9): 1260–1266. https://doi.org/10.1001/jamaoncol.2023.1962
Gan HK, Millward M, Hua Y, et al., 2019, First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity. Clin Cancer Res, 25(16): 4924–4932. https://doi.org/10.1158/1078-0432.CCR-18-1189
Cadoo K, Simpkins F, Mathews C, et al., 2022, Olaparib Treatment for Platinum-Sensitive Relapsed Ovarian Cancer by BRCA Mutation and Homologous Recombination Deficiency Status: Phase II LIGHT Study Primary Analysis. Gynecologic Oncology, 166(3): 425–431. https://doi.org/10.1016/j.ygyno.2022.06.017
Mirza MR, Monk BJ, Herrstedt J, et al., 2016, Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med, 375: 2154–2164. https://doi.org/10.1056/NEJMoa1611310
Swisher EM, Lin KK, Oza AM, et al., 2017, Rucaparib in Relapsed, Platinum-Sensitive High-Grade Ovarian Carcinoma (ARIEL2 Part 1): An International, Multicentre, Open-Label, Phase 2 Trial. The Lancet Oncology, 18(1): 75–87. https://doi.org/10.1016/S1470-2045(16)30559-9
Luo J, Gao B, Lin Z, et al., 2022, Efficacy and Safety of Lenvatinib Versus Sorafenib in First-Line Treatment of Advanced Hepatocellular Carcinoma: A Meta-Analysis. Front Oncol, 12: 1010726. https://doi.org/10.3389/fonc.2022.1010726
Li J, Qin S, Xu R-H, et al., 2018, Effect of Fruquintinib vs Placebo on Overall Survival in Patients with Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. JAMA, 319(24): 2486–2496. https://doi.org/10.1001/jama.2018.7855
Han B, Li K, Zhao Y, et al., 2018, Anlotinib as a Third-Line Therapy in Patients with Refractory Advanced Non-Small Cell Lung Cancer: A Multicentre, Randomised Phase II Trial (ALTER0302). Br J Cancer, 118: 654–661. https://doi.org/10.1038/bjc.2017.478
Wang D-R, Wu X-L, Sun Y-L, 2022, Therapeutic Targets and Biomarkers of Tumor Immunotherapy: Response Versus Non-Response. Signal Transduction and Target Therapy, 7: 331. https://doi.org/10.1038/s41392-022-01136-2
Patsoukis N, Wang Q, Strauss L, et al., 2020, Revisiting the PD-1 Pathway. Science Advances, 6(38): eabd2712. https://doi.org/10.1126/sciadv.abd2712
Lisi L, Lacal PM, Martire M, et al., 2022, Clinical Experience with CTLA-4 Blockade for Cancer Immunotherapy: From the Monospecific Monoclonal Antibody Ipilimumab to Probodies and Bispecific Molecules Targeting the Tumor Microenvironment. Pharmacological Research, 175: 105997. https://doi.org/10.1016/j.phrs.2021.105997
Li H, Saw PE, Song E, 2020, Challenges and Strategies for Next-Generation Bispecific Antibody-Based Antitumor Therapeutics. Cellular & Molecular Immunology, 17: 451–461. https://doi.org/10.1038/s41423-020-0417-8
Zhang Z, Luo F, Cao J, et al., 2021, Anticancer Bispecific Antibody R&D Advances: A Study Focusing on Research Trend Worldwide and in China. Journal of Hematology & Oncology, 14: 124. https://doi.org/10.1186/s13045-021-01126-x
Pang X, Huang Z, Zhong T, et al., 2023, Cadonilimab, A Tetravalent PD-1/CTLA-4 Bispecific Antibody with Trans-Binding and Enhanced Target Binding Avidity. mAbs, 15(1): 2180794. https://doi.org/10.1080/19420862.2023.2180794
Li J, 2019, Diarrhea with HER2-Targeted Agents in Cancer Patients: A Systematic Review and Meta-Analysis. The Journal of Clinical Pharmacology, 59(7): 935–946. https://doi.org/10.1002/jcph.1382
Raja Sharin RNFS, Khan J, Ibahim MJ, et al., 2022, Role of ErbB1 in the Underlying Mechanism of Lapatinib-Induced Diarrhea: A Review. BioMed Research International, 2022: 4165808. https://doi.org/10.1155/2022/4165808
Su Q, Zhang X, Shen X, et al., 2018, Risk of Immune-Related Colitis with PD-1/PD-L1 Inhibitors vs Chemotherapy in Solid Tumors: Systems Assessment. J Cancer, 9(9): 1614–1622. https://doi.org/10.7150/jca.24200
Kornblau S, Benson AB III, Catalano R, et al., 2000, Management of Cancer Treatment-Related Diarrhea: Issues and Therapeutic Strategies. Journal of Pain and Symptom Management, 19(2): 118–129. https://doi.org/10.1016/s0885-3924(99)00149-9
Chitapanarux I, Chitapanarux T, Traisathit P, et al., 2010, Randomized Controlled Trial of Live Lactobacillus Acidophilus Plus Bifidobacterium Bifidum in Prophylaxis of Diarrhea During Radiotherapy in Cervical Cancer Patients. Radiation Oncology, 5: 31. https://doi.org/10.1186/1748-717x-5-31
Tang L, Li X, Wan L, et al., 2019, Herbal Medicines for Irinotecan-Induced Diarrhea. Front Pharmacol, 10: 182. https://doi.org/10.3389/fphar.2019.00182
Wang S-Y, Wang Z-H, Li C-Y, et al., 2021, Research Progress on Diarrhea Induced by Molecular-Targeted Agents. Acta Pharmaceutica Sinica, 56(12): 3377–3384. https://doi.org/10.16438/j.0513-4870.2021-0427
Mori K, Kondo T, Kamiyama Y, et al., 2003, Preventive Effect of Kampo Medicine (Hangeshashin-to) Against Irinotecan-Induced Diarrhea in Advanced Non-Small-Cell Lung Cancer. Cancer Chemotherapy and Pharmacology, 51: 403–406. https://doi.org/10.1007/s00280-003-0585-0